Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114674 | 0.89 | MEN1 (0.52) | CNR2MAPK1 | |
| SCHEMBL1114228 | 0.88 | TP53 (0.51) | SMN1; SMN2MAPT | |
| SCHEMBL3247134 | 0.86 | P2RX7 (0.41) | HDAC1HDAC6 | |
| SCHEMBL1114188 | 0.86 | RIPK1 (0.42) | MAPT | |
| SCHEMBL1114466 | 0.86 | ALDH1A1 (0.46) | MAPK1MAPT | |
| SCHEMBL1114523 | 0.85 | MAOB (0.46) | HDAC1HDAC8HDAC6MAPK1 | |
| SCHEMBL13447621 | 0.84 | MAOB (0.41) | HDAC1HDAC8HDAC6MAPK1 | |
| SCHEMBL3243966 | 0.83 | HDAC4 (0.46) | SMN1; SMN2HDAC1HDAC8HDAC6MAPK1 | |
| SCHEMBL1114342 | 0.83 | HDAC1 (0.40) | SMN1; SMN2HDAC1HDAC8HDAC6 | |
| SCHEMBL1114271 | 0.82 | HDAC1 (0.39) | SMN1; SMN2HDAC1HDAC8HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | claimed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | claimed |
| EP-2278879-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009131957-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | claimed |
| EP-2278879-B1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING OXADIAZOLE DERIVATIVES | PATH DRUG SOLUTIONS (US) | 2016-06-15 | — | — | EP | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796321-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | PATH DRUG SOLUTIONS (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207205-B2 | Compounds, compositions and methods comprising oxadiazole derivatives | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 4546/4885HDAC1 2458/4885KDM1A 4807/4885 |
| US-20090264441-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 3726/4885HDAC1 2122/4885KDM1A 4731/4885 |
| US-20120264717-A1 | Compounds, Compositions and Methods Comprising Oxadiazole Derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 3726/4885HDAC1 2122/4885KDM1A 4731/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | SMN1; SMN2 4546/4885HDAC1 2458/4885KDM1A 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.